Sangamo Therapeutics' GAAP loss for 3 months of 2022 was $43.977 million, down 4.3% from $45.939 million in the prior year. Revenue increased 7.4% to $28.231 million from $26.28 million a year earlier.

Sangamo Therapeutics' GAAP loss for 2021 was $178.297 million, up 47.2% from $121.122 million in the prior year. Revenue declined 6.3% to $110.701 million from $118.192 million a year earlier.

Sangamo Therapeutics' GAAP loss for 9M 2021 was $140.801 million, up 75% from $80.447 million in the previous year. Revenue declined 10.5% to $82.715 million from $92.392 million a year earlier.

Sangamo Therapeutics' GAAP loss for six months of 2021 was $93.113 million, up 18% from $78.939 million in the previous year. Revenue increased 56.4% to $54.152 million from $34.629 million a year earlier.